Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

LDL Target Post-CABG in Non-Diabetic Patients

Risk Stratification and Treatment Targets

  • Post-CABG patients without diabetes are considered very high cardiovascular risk by definition, as they have established atherosclerotic cardiovascular disease (ASCVD) requiring surgical revascularization, and should have an LDL-C target of <55 mg/dL (<1.4 mmol/L) 1

Specific LDL-C Targets and Treatment Strategy

  • The primary target for LDL-C in post-CABG patients is <55 mg/dL (<1.4 mmol/L), which is the contemporary guideline-recommended target for all patients with established ASCVD, including post-CABG patients 1
  • High-intensity statin therapy should be initiated or continued immediately when the patient can take oral medications post-operatively, as discontinuation of statins perioperatively increases mortality risk and should be avoided 2
  • If LDL-C remains >55 mg/dL after 4-6 weeks on high-intensity statin, add ezetimibe 10 mg daily to the statin regimen, and reassess LDL-C in another 4-6 weeks 1
  • If LDL-C still remains >55 mg/dL despite statin plus ezetimibe, add a PCSK9 inhibitor (alirocumab, evolocumab subcutaneously every 2-4 weeks, or inclisiran subcutaneously twice yearly) 1

Monitoring and Follow-Up

  • Measure LDL-C at 4-6 weeks after each treatment adjustment to assess target attainment and guide therapy escalation 1
  • Do not delay escalation - if targets are not met at 4-6 weeks, immediately add the next agent rather than continuing suboptimal therapy 1
  • Do not stop statins perioperatively - continuation through the surgical period is associated with reduced mortality 2

LDL Cholesterol Management Post-CABG

Target LDL Levels

  • For patients who have undergone coronary artery bypass grafting (CABG), the LDL cholesterol should be reduced to less than 70 mg/dL in very high-risk patients, and at minimum to less than 100 mg/dL for all CABG patients. 3, 4
  • For very high-risk patients, it is reasonable to lower LDL cholesterol to less than 70 mg/dL. 3, 4
  • Very high-risk features include: multiple major risk factors (especially diabetes), severe and poorly controlled risk factors (especially continued smoking), multiple risk factors of metabolic syndrome, and acute coronary syndromes. 5, 6

Statin Therapy Recommendations

  • All patients undergoing CABG should receive statin therapy unless contraindicated. 3, 4
  • Statins should be continued without interruption before and after CABG in patients without adverse reactions to therapy. 7, 8, 5
  • An adequate dose of statin should be used to achieve at least a 30% lowering of LDL cholesterol. 3, 4
  • High-intensity statin therapy should be the foundation of lipid management post-CABG. 3, 4
  • For patients undergoing urgent or emergency CABG who are not already taking a statin, it is reasonable to initiate high-dose statin therapy immediately. 3, 4
  • Discontinuation of statin therapy before or after CABG is not recommended and may increase cardiovascular risk. 7, 8, 5
  • Regular lipid monitoring is essential to ensure targets are being maintained over time. 3, 4

REFERENCES